Metabolism
Serine/threonine kinase AMPK upregulates glucose uptake by promoting the expression and function of glucose transporters. AMPK is activated by increased AMP/ATP ratio, resulting from cellular and environmental stress, e.g. low glucose, heat shock, hypoxia and ischemia. AMPK activation positively modulates signaling transductions that refill ATP levels. Moreover, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis through inhibition of ACC and activation of PFK2. AMPK negatively regulates various proteins which are important to ATP-consuming mechanisms, e.g. mTORC2, glycogen synthase, SREBP-1, and TSC2, causing the downregulation/inhibition of gluconeogenesis and glycogen, lipid and protein synthesis.
-
A8703 IsosafroleTarget: Lactate Dehydrogenases (LDH)Summary: A stiripentol analog, a potent LDH inhibitor.
-
A3358 DeltarasinTarget: Phosphodiesterases (PDEs)Summary: KRAS-PDEδ interaction inhibitor
-
A3493 INCB024360 analogueSummary: potent and selective inhibitor of IDO1
-
A4068 SNX-21121 CitationSummary: Hsp90 inhibitor,ATP-competitve,potent and selective
-
A8202 Abiraterone acetateTarget: Cytochrome P450 (CYP450)Summary: Cytochrome p450 17a1 inhibitor
-
A4300 GW96621 CitationSummary: PPARγ antagonist
-
A4302 Rosiglitazone maleateTarget: Insulin and Insulin-like ReceptorsSummary: PPARγ agonist,high-affinity and selective,potent insulin sensitizer
-
A4303 GSK3787Summary: PPARβ/δ antagonist,novel and irreversible
-
A4304 RosiglitazoneSummary: Potent PPARγ agonist
-
A4305 WY-14643 (Pirinixic Acid)1 CitationTarget: PPARSummary: PPARα agonist,selective and highly potent